Abstract
Early recognition is indispensable for the optimal management of Acute Coronary Syndrome (ACS); moreover, early prognostic stratification of patients with established ACS is useful to improve strategies for these patients. The paper focuses attention on troponins (I and T), the most validated biomarker for early diagnosis of ACS and on B-type natriuretic peptide (BNP) and N-terminal proB-type natriuretic peptide (NT-proBNP), the most powerful cardiac marker after troponin to be used as prognostic indicator in patients with ACS. We pay particular attention to the troponin story in ACS, including discussions about high sensitivity methods and on the most recent techniques (e.g. Point Of Care) available to shorten times from the blood sampling to the validated report [Turn around time (TAT) arm-to-report]. We report the differences between BNP and NT-proBNP, both from an analytical and a clinical point of view and discuss the use of cardiac natriuretic peptides for early recognition of cardiac insufficiency and early management of patients presenting to Emergency Departments with dyspnoea. Finally, we briefly discuss the most promising new cardiac markers actually used only in preclinical studies.
Keywords: Acute coronary syndromes, troponin, natriuretic peptide, point of care, cardiac markers
Current Vascular Pharmacology
Title: Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Volume: 8 Issue: 3
Author(s): Gianfranco Amodio, Gianfranco Antonelli and Francesca Di Serio
Affiliation:
Keywords: Acute coronary syndromes, troponin, natriuretic peptide, point of care, cardiac markers
Abstract: Early recognition is indispensable for the optimal management of Acute Coronary Syndrome (ACS); moreover, early prognostic stratification of patients with established ACS is useful to improve strategies for these patients. The paper focuses attention on troponins (I and T), the most validated biomarker for early diagnosis of ACS and on B-type natriuretic peptide (BNP) and N-terminal proB-type natriuretic peptide (NT-proBNP), the most powerful cardiac marker after troponin to be used as prognostic indicator in patients with ACS. We pay particular attention to the troponin story in ACS, including discussions about high sensitivity methods and on the most recent techniques (e.g. Point Of Care) available to shorten times from the blood sampling to the validated report [Turn around time (TAT) arm-to-report]. We report the differences between BNP and NT-proBNP, both from an analytical and a clinical point of view and discuss the use of cardiac natriuretic peptides for early recognition of cardiac insufficiency and early management of patients presenting to Emergency Departments with dyspnoea. Finally, we briefly discuss the most promising new cardiac markers actually used only in preclinical studies.
Export Options
About this article
Cite this article as:
Amodio Gianfranco, Antonelli Gianfranco and Di Serio Francesca, Cardiac Biomarkers in Acute Coronary Syndromes: A Review, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112250
DOI https://dx.doi.org/10.2174/157016110791112250 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry Total Lipids and Fatty Acid Methyl Esters of Germinated Seeds of Mangrove Wild Legume
Current Nutrition & Food Science Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Autophagy and Heart Disease: Implications for Cardiac Ischemia- Reperfusion Damage
Current Molecular Medicine Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Associations between Alzheimer’s Disease and Blood Homocysteine, Vitamin B<sub>12</sub>, and Folate: A Case-Control Study
Current Alzheimer Research Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Foods for Health and to Treat Diseases
Current Pediatric Reviews Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Editorial [Hot Topic:Translating Clinical Evidence into the Practice of Diabetes Care (Guest Editor: Richard W. Grant Contents)]
Current Diabetes Reviews Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Blood Serum Atherogenicity and Coronary Artery Calcification
Current Pharmaceutical Design The Assessment of Platelet Activation in Antiplatelet Drug Development
Current Medicinal Chemistry Rheumatoid Arthritis and Cardiovascular Risk: Between Lights and Shadows
Current Rheumatology Reviews